Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,112.89
(
-0.18%
)
US TECH 100
25,879.20
(
-0.29%
)
Dow Jones
49,463.35
(
0.03%
)
Brent Oil
90.84
(
-1.96%
)
Bitcoin
75,207.31
(
1.82%
)
News Focus
News Focus
Post# of 257426
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122876
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 222593

Monday, 12/03/2018 2:28:15 PM

Monday, December 03, 2018 2:28:15 PM

Post# of 257426

the market absolutely hates this deal for GSK...

The reason is that the deal won't be accretive to GSK's EPS until 2022 at the earliest.

GSK essentially got out of oncology in 2014—just as the sector was heating up. So, now they may be overcompensating to some degree in getting back in.

Still, PARP inhibitors have a lot of upside, so I can’t say for sure that this deal is a mistake.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today